Same love, smaller allowance
Oppenheimer basically told IBM: “We still like you, but we’re not buying the jumbo combo anymore.” The firm held its Outperform rating on the stock on April 16, 2026, while cutting its price target from $380 to $320.
Why investors should care
That kind of move matters because price targets are Wall Street’s way of saying how much upside it thinks is left in the tank. A cut like this doesn’t scream disaster, but it does hint that analysts are dialing back expectations for IBM’s growth or market multiple.
The vibe check
A few things are doing the heavy lifting in the background:
- IBM was already trading at $250.76, so the new target still leaves room, just less runway than before.
- The stock was flagged as overvalued versus GF Value™ at $210.85.
- Insider buying over the last three months totaled about $417K, which is a nice little vote of confidence, even if it doesn’t override the analyst chatter.
Big picture
This is less “IBM is broken” and more “the bar got lowered.” For investors, the real question is whether IBM can keep proving it deserves premium treatment — or whether Wall Street keeps shaving targets until the story feels a little more like a value play and a little less like a growth one.